Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

NCT05825443 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Immunotherapy
Chemotherapy

Interventions

DRUG: Camrelizumab

Sponsor

Nanfang Hospital, Southern Medical University

Collaborators

[object Object]